Journal article
Columba de la Parra, Luis D Borrero-Garcia, Ailed M Cruz-Collazo, R. Schneider, S. Dharmawardhane
Journal of Biological Chemistry, 2015
Journal of Biological Chemistry, 2015
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
de la Parra, C., Borrero-Garcia, L. D., Cruz-Collazo, A. M., Schneider, R., & Dharmawardhane, S. (2015). Equol, an Isoflavone Metabolite, Regulates Cancer Cell Viability and Protein Synthesis Initiation via c-Myc and eIF4G*. Journal of Biological Chemistry.
Chicago/Turabian
Click to copy
Parra, Columba de la, Luis D Borrero-Garcia, Ailed M Cruz-Collazo, R. Schneider, and S. Dharmawardhane. “Equol, an Isoflavone Metabolite, Regulates Cancer Cell Viability and Protein Synthesis Initiation via c-Myc and eIF4G*.” Journal of Biological Chemistry (2015).
MLA
Click to copy
de la Parra, Columba, et al. “Equol, an Isoflavone Metabolite, Regulates Cancer Cell Viability and Protein Synthesis Initiation via c-Myc and eIF4G*.” Journal of Biological Chemistry, 2015.
BibTeX Click to copy
@article{columba2015a,
title = {Equol, an Isoflavone Metabolite, Regulates Cancer Cell Viability and Protein Synthesis Initiation via c-Myc and eIF4G*},
year = {2015},
journal = {Journal of Biological Chemistry},
author = {de la Parra, Columba and Borrero-Garcia, Luis D and Cruz-Collazo, Ailed M and Schneider, R. and Dharmawardhane, S.}
}
Abstract
Background: Equol, a daidzein metabolite, is a potent regulator of the cancer-promoting effects of dietary daidzein. Results: Silencing of eIF4G or c-Myc demonstrated that the equol-mediated c-Myc up-regulation is central to the pro-cancer effects of equol. Conclusion: Equol may promote cancer via c-Myc. Significance: Caution must be exercised regarding soyfood consumption for patients with ER (−) breast cancer. Epidemiological studies implicate dietary soy isoflavones as breast cancer preventives, especially due to their anti-estrogenic properties. However, soy isoflavones may also have a role in promoting breast cancer, which has yet to be clarified. We previously reported that equol, a metabolite of the soy isoflavone daidzein, may advance breast cancer potential via up-regulation of the eukaryotic initiation factor 4GI (eIF4GI). In estrogen receptor negative (ER−) metastatic breast cancer cells, equol induced elevated levels of eIF4G, which were associated with increased cell viability and the selective translation of mRNAs that use non-canonical means of initiation, including internal ribosome entry site (IRES), ribosome shunting, and eIF4G enhancers. These mRNAs typically code for oncogenic, survival, and cell stress molecules. Among those mRNAs translationally increased by equol was the oncogene and eIF4G enhancer, c-Myc. Here we report that siRNA-mediated knockdown of c-Myc abrogates the increase in cancer cell viability and mammosphere formation by equol, and results in a significant down-regulation of eIF4GI (the major eIF4G isoform), as well as reduces levels of some, but not all, proteins encoded by mRNAs that are translationally stimulated by equol treatment. Knockdown of eIF4GI also markedly reduces an equol-mediated increase in IRES-dependent mRNA translation and the expression of specific oncogenic proteins. However, eIF4GI knockdown did not reciprocally affect c-Myc levels or cell viability. This study therefore implicates c-Myc as a potential regulator of the cancer-promoting effects of equol via up-regulation of eIF4GI and selective initiation of translation on mRNAs that utilize non-canonical initiation, including certain oncogenes.
